Literature DB >> 29307327

Transparency in practice: Evidence from 'verification analyses' issued by the Polish Agency for Health Technology Assessment in 2012-2015.

Piotr Ozierański1, Olga Löblová2, Natalia Nicholls1, Marcell Csanádi3, Zoltán Kaló4, Martin McKee5, Lawrence King6.   

Abstract

Transparency is recognised to be a key underpinning of the work of health technology assessment (HTA) agencies, yet it has only recently become a subject of systematic inquiry. We contribute to this research field by considering the Polish Agency for Health Technology Assessment (AHTAPol). We situate the AHTAPol in a broader context by comparing it with the National Institute for Health and Care Excellence (NICE) in England. To this end, we analyse all 332 assessment reports, called verification analyses, that the AHTAPol issued from 2012 to 2015, and a stratified sample of 22 Evidence Review Group reports published by NICE in the same period. Overall, by increasingly presenting its key conclusions in assessment reports, the AHTAPol has reached the transparency standards set out by NICE in transparency of HTA outputs. The AHTAPol is more transparent than NICE in certain aspects of the HTA process, such as providing rationales for redacting assessment reports and providing summaries of expert opinions. Nevertheless, it is less transparent in other areas of the HTA process, such as including information on expert conflicts of interest. Our findings have important implications for understanding HTA in Poland and more broadly. We use them to formulate recommendations for policymakers.

Year:  2018        PMID: 29307327     DOI: 10.1017/S1744133117000342

Source DB:  PubMed          Journal:  Health Econ Policy Law        ISSN: 1744-1331


  2 in total

1.  NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.

Authors:  Ash Bullement; Matthew Taylor; Sam Thomas McMordie; Errol Waters; Anthony James Hatswell
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 2.  Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.

Authors:  Piotr Ozieranski; Luc Martinon; Pierre-Alain Jachiet; Shai Mulinari
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.